Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 11
Submit an article Journal homepage
719
Views
36
CrossRef citations to date
0
Altmetric
Research Article

Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases

Germán Campuzano-ZuluagaDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, FL, USACorrespondence[email protected] [email protected]
,
Maureen Cioffi-LavinaDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, FL, USA
,
Izidore S. LossosDivision of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center and Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USACorrespondence[email protected] [email protected]
&
Jennifer R. Chapman-FredricksDivision of Hematopathology, Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, FL, USA
Pages 2405-2411 | Received 10 Jan 2013, Accepted 18 Feb 2013, Published online: 04 Apr 2013

Citations (36)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Shinichi Makita, Dai Maruyama & Kensei Tobinai. (2020) Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. OncoTargets and Therapy 13, pages 5993-6009.
Read now
María Queralt Salas, Fina Climent, Gustavo Tapia, Eva DomingoDomènech, Santiago Mercadal, Ana Carla Oliveira, Carmen Aguilera, García Olga, Miriam Moreno Velázquez, Marcio Andrade-Campos, Maite Encuentra, Alberto Fernández de Sevilla, Anna Sureda, Juan Manuel Sancho & Eva González-Barca. (2020) Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers 25:1, pages 69-75.
Read now
Nancy L. Bartlett, Mitchell R. Smith, Tanya Siddiqi, Ranjana H. Advani, Owen A. O’Connor, Jeff P. Sharman, Tatyana Feldman, Kerry J. Savage, Andrei R. Shustov, Catherine S. Diefenbach, Yasuhiro Oki, Maria Corinna Palanca-Wessels, Mayur Uttarwar, Martha Li, Jing Yang & Eric D. Jacobsen. (2017) Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia & Lymphoma 58:7, pages 1607-1616.
Read now
Lakshminarayanan Nandagopal & Amitkumar Mehta. (2017) Treatment approaches of hard-to-treat non-Hodgkin lymphomas. Expert Review of Hematology 10:3, pages 259-273.
Read now
John Matthew R. Pierce & Amitkumar Mehta. (2017) Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Review of Hematology 10:1, pages 29-37.
Read now
Alexandra Papoudou-Bai, Anna Goussia, Anna Batistatou, Dimitrios Stefanou, Vassiliki Malamou-Mitsi & Panagiotis Kanavaros. (2016) The expression levels of JunB, JunD and p-c-Jun are positively correlated with tumor cell proliferation in diffuse large B-cell lymphomas. Leukemia & Lymphoma 57:1, pages 143-150.
Read now
Wenli Zheng, L. Jeffrey Medeiros, Ken H. Young, Maitrayee Goswami, Linda Powers, Hagop H. Kantarjian, Deborah A. Thomas, Jorge E. Cortes & Sa A. Wang. (2014) CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leukemia & Lymphoma 55:3, pages 624-627.
Read now
Francisco Vega. (2013) Time to look for CD30 expression in diffuse large B-cell lymphomas, along the way to immunotherapy. Leukemia & Lymphoma 54:11, pages 2341-2342.
Read now

Articles from other publishers (28)

Taylor R. Brooks & Paolo F. Caimi. (2023) A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Reviews, pages 101140.
Crossref
Deepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, Youn Kim, Eric Jacobsen, Madeleine Duvic, Meredith Little, William Trepicchio, Keenan Fenton, Matthew Onsum, Julie Lisano & Ranjana Advani. (2022) Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. The Oncologist 27:10, pages 864-873.
Crossref
Roland SchwartingEric BehlingAshleigh AllenVivian Arguello-GuerraTulin Budak-Alpdogan. (2022) CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies. Archives of Pathology & Laboratory Medicine 146:4, pages 415-432.
Crossref
Claudio Ortolani. 2021. Flow Cytometry of Hematological Malignancies. Flow Cytometry of Hematological Malignancies 301 427 .
David W. Meyer, Fu Li & Robert P. Lyon. 2021. Quantitative Analysis of Cellular Drug Transport, Disposition, and Delivery. Quantitative Analysis of Cellular Drug Transport, Disposition, and Delivery 357 382 .
Mina L. Xu, Ali Gabali, Eric D. Hsi, Yuri Fedoriw, Kiran Vij, Mohamed E. Salama, Radhakrishnan Ramchandren, Dennis O’Malley, Mark R. Wick, Maxime Battistella & Alejandro A. Gru. (2020) Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. American Journal of Surgical Pathology 44:2, pages e1-e14.
Crossref
Samer Nassif, Ziad M. El-Zaatari, Michel Attieh, Maya Hijazi, Najla Fakhreddin, Tarek Aridi & Fouad Boulos. (2019) Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics. Medicine 98:32, pages e16702.
Crossref
Shuanghui Yang, Huan Li, Ling Xu, Zhenhan Deng, Wei Han, Yanting Liu, Wenqi Jiang & Youli Zu. (2018) Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies. Molecular Therapy - Nucleic Acids 13, pages 164-175.
Crossref
Qi-Xing Gong, Zhen Wang, Chong Liu, Xiao Li, Ting-Xun Lu, Jin-Hua Liang, Wei Xu, Jian-Yong Li & Zhi-Hong Zhang. (2018) CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. Journal of Clinical Pathology 71:9, pages 795-801.
Crossref
Marc A. Weniger, Enrico Tiacci, Stefanie Schneider, Judith Arnolds, Sabrina Rüschenbaum, Janine Duppach, Marc Seifert, Claudia Döring, Martin-Leo Hansmann & Ralf Küppers. (2018) Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells. Journal of Clinical Investigation 128:7, pages 2996-3007.
Crossref
David D.W. Twa, Anja Mottok, Kerry J. Savage & Christian Steidl. (2018) The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies. Blood Reviews 32:3, pages 249-255.
Crossref
Fu Li, Michelle Ulrich, Mechthild Jonas, Ivan J. Stone, Germein Linares, Xinqun Zhang, Lori Westendorf, Dennis R. Benjamin & Che-Leung Law. (2017) Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates. Molecular Cancer Therapeutics 16:7, pages 1347-1354.
Crossref
Jie Xu, Yasuhiro Oki, Annapurna Saksena, Parth Desai, Pei Lin, Guilin Tang, C. Cameron Yin, M. James You, Beenu Thakral, L. Jeffrey Medeiros & Shaoying Li. (2017) CD30 expression and prognostic significance in R-EPOCH–treated patients with diffuse large B-cell lymphoma. Human Pathology 60, pages 160-166.
Crossref
Jun Ho YiSeok Jin KimWon Seog Kim. (2017) Brentuximab vedotin: clinical updates and practical guidance. Blood Research 52:4, pages 243.
Crossref
Geetika Bhatt, Kami Maddocks & Beth Christian. (2016) CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. Current Hematologic Malignancy Reports 11:6, pages 480-491.
Crossref
Michael T. Tees & Lubomir Sokol. (2016) Novel Immunotherapies for B-Cell Lymphomas and Leukemias. American Journal of Therapeutics 23:5, pages e1157-e1181.
Crossref
Jozef Malysz, Patrick Erdman, Jeremy Klapper, Junjia Zhu, Michael Creer & Michael G. Bayerl. (2016) Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia 16:8, pages 429-433.
Crossref
Santiago Montes-Moreno. (2016) Targeting CD30 expression in diverse Large B-cell lymphoma entities. European Journal of Haematology 97:1, pages 7-8.
Crossref
Xuan J. Wang, Adam C. Seegmiller, Nishitha M. Reddy & Shaoying Li. (2016) CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma . European Journal of Haematology 97:1, pages 39-47.
Crossref
Penelope Korkolopoulou, Theodoros Vassilakopoulos, Vassilios Milionis & Maria Ioannou. (2016) Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. Advances in Anatomic Pathology 23:4, pages 202-243.
Crossref
Matthew J. Barth, Yaya Chu, Patrick J. Hanley & Mitchell S. Cairo. (2016) Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. British Journal of Haematology 173:4, pages 597-616.
Crossref
Dennis P. O'Malley, Aaron Auerbach & Lawrence M. Weiss. (2015) Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas. Archives of Pathology & Laboratory Medicine 139:9, pages 1094-1107.
Crossref
Yann Charli-Joseph, Lorenzo Cerroni & Philip E. LeBoit. (2015) Cutaneous Spindle-Cell B-Cell Lymphomas. American Journal of Surgical Pathology 39:6, pages 737-743.
Crossref
Xiaoxiao Hao, Xiaolei Wei, Fen Huang, Yongqiang Wei, Hong Zeng, Linwei Xu, Qinjun Zhou & Ru Feng. (2015) The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma. PLOS ONE 10:5, pages e0126615.
Crossref
Eric D. JacobsenJeff P. SharmanYasuhiro OkiRanjana H. AdvaniJane N. WinterCeleste M. BelloGary SpitzerMaria Corinna Palanca-Wessels, Dana A. Kennedy, Pamela Levine, Jing Yang & Nancy L. Bartlett. (2015) Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 125:9, pages 1394-1402.
Crossref
Graham W. Slack, Christian Steidl, Laurie H. Sehn & Randy D. Gascoyne. (2014) CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia . British Journal of Haematology 167:5, pages 608-617.
Crossref
Yehuda E Deutsch, Izidore S Lossos & Joseph D Rosenblatt. (2013) Brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: a review of clinical experience and future directions. International Journal of Hematologic Oncology 2:6, pages 455-465.
Crossref
Ka-To Shum, Jiehua Zhou & John J. Rossi. (2013) Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. Journal of Cancer Therapy 04:04, pages 872-890.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.